

Humana

Healthy Horizons.[®]
in Louisiana

<u>Notification:</u>	<u>HUM 7802</u>
<u>Category:</u>	<u>HCPCS - Drugs & Biologicals</u>
<u>Topic:</u>	<u>Louisiana Medicaid: fam-trastuzumab deruxtecan – HCPCS code J9358</u>
<u>What is changing? / Change Description:</u>	<p><u>We do not reimburse charges of HCPCS code J9358 if billed with any of the following diagnosis:</u></p> <ul style="list-style-type: none"> • <u>HER2-overexpressing biliary tract cancer</u> • <u>HER-2 overexpressing cervical cancer</u> • <u>HER2-overexpressing endometrial carcinoma</u> • <u>HER2-overexpressing occult primary</u> • <u>HER2-overexpressing ovarian cancer</u> • <u>HER2-overexpressing pancreatic adenocarcinoma</u> • <u>HER2-overexpressing salivary gland tumors</u> • <u>HER2-overexpressing small bowel adenocarcinoma</u> • <u>HER2-overexpressing urothelial carcinoma</u> • <u>HER2-overexpressing vaginal cancer</u> • <u>HER2-overexpressing vulvar cancer</u> <p><u>Unless either of the following also occurs:</u></p> <ul style="list-style-type: none"> • <u>HER2 testing has been billed in the patient's lifetime</u> • <u>Pertuzumab, pertuzumab trastuzumab hyaluronidase, margetuximab, ado-trastuzumab emtansine, trastuzumab, trastuzumab hyaluronidase or fam-trastuzumab deruxtecan have not been billed within the past year</u>
<u>Why is Humana making this change? / Change Reason:</u>	<u>According to the FDA-approved package insert and prescribing information and the pharmaceutical compendia, the patient should have previously tested HER2 positive or had a previous trastuzumab-based therapy.</u>
<u>Language:</u>	<u>English</u>
<u>Impacted Products:</u>	<u>Medicaid- Louisiana</u>